Preladenant

Preladenant
(IUPAC) ime
	2-(2-Furanil)-7-[2-[4-[4-(2-metoksietoksi)fenil]-1-piperazinil]etil]7H-pirazolo[4,3-e][1,2,4]triazolo[1,5-c]pirimidin-5-amin
Klinički podaci
Identifikatori
CAS broj	377727-87-2
ATC kod	nije dodeljen
PubChem	10117987
UNII	950O97NUPO
Hemijski podaci
Formula	C25H29N9O3
Mol. masa	503,555 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C25H29N9O3/c1-35-15-16-36-19-6-4-18(5-7-19)32-11-8-31(9-12-32)10-13-33-23-20(17-27-33)24-28-22(21-3-2-14-37-21)30-34(24)25(26)29-23/h2-7,14,17H,8-13,15-16H2,1H3,(H2,26,29) ; Key: DTYWJKSSUANMHD-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Investigational
Način primene	Oralno

Preladenant (SCH 420814) je lek koji deluje kao potentan i selektivan antagonist adenozinskog A_2A receptora. On se izučava kao mogući tretman za Parkinsonovu bolest.^[3] Pozitivni rezultati su objavljeni u fazi II kliničkih ispitivanja.^[4]

Reference[uredi | uredi kod]

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hodgson RA, Bertorelli R, Varty GB, Lachowicz JE, Forlani A, Fredduzzi S, Cohen-Williams ME, Higgins GA, Impagnatiello F, Nicolussi E, Parra LE, Foster C, Zhai Y, Neustadt BR, Stamford AW, Parker EM, Reggiani A, Hunter JC (March 2009). „Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 in Rodent Models of Movement Disorders and Depression”. The Journal of Pharmacology and Experimental Therapeutics 330 (1): 294–303. DOI:10.1124/jpet.108.149617. PMID 19332567.
↑ Hauser, R. A.; Cantillon, M.; Pourcher, E.; Micheli, F.; Mok, V.; Onofrj, M.; Huyck, S.; Wolski, K. (2011). „Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial”. The Lancet Neurology 10 (3): 221–229. DOI:10.1016/S1474-4422(11)70012-6.

	Portal Medicina
	Portal Hemija